- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Sharon Phares Speaks on How Value Assessments Can Improve Care Imbalances for Women
Marking Women's Health Month, Sharon Phares, PhD, MPH, chief scientific officer of the National Pharmaceutical Council, detailed how value assessments can address health care imbalances for women.
Sharon Phares, PhD, MPH, chief scientific officer of the National Pharmaceutical Council, detailed how value assessments can address health care imbalances for women, marking Women's Health Month.
Transcript
How do value assessments currently address imbalances in health care for women and what still needs to be improved?
Phares: So, currently, there are attempts to address imbalances but they still exist. For instance, if you think back to when migraine medications were being assessed, a lot of the issues that really impact what makes those medications important to women in particular, who are the most predominant group that suffers from migraine, we're not considered. So, those are things like their ability to function and to care for their families. What they're trying to do in HTA [health technology assessment] now is to be more inclusive of those; to look at things like caregiver burden, again, something that women are more likely to be doing than men; and then quality of life issues around your ability to do normal activities, like care for children, go to work, etc.
The Challenge of Addressing Drug Spend to Drive Down Total Cost of Care in EOM
October 27th 2024Stuart Staggs, vice president of transformation and shared services at McKesson, explained that oncology practices in the Enhancing Oncology Model (EOM) have a tough job driving down costs when drug costs make up a larger portion of the total cost of care.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Targeting Progression: Amivantamab’s Role in NSCLC After Osimertinib
October 24th 2024Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 trials.
Read More
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
